Novel Biomarkers in Alzheimer's Disease

Guest Editor:

Dr. Chiara Villa
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

Deadline for manuscript submissions:
closed (5 July 2020)

Message from the Guest Editor

Dear Colleagues,

Alzheimer's disease (AD) is the most common form of dementia in the elderly, affecting about 46million people worldwide. It is clinically characterized by the progressive deterioration of memory and other cognitive functions that results in the loss of autonomy and which ultimately requires full-time medical care. The diagnosis of AD currently relies on clinical criteria, including mental status assessment, neurological examination, and brain imaging tests. However, these imaging methods are conclusive only in the advanced stages of disease, whereas AD physiopathology begins several decades before onset of the first symptoms. It is therefore particularly important to identify potential biomarkers that can be used in the early detection of AD, i.e., before clinical signs appear, as well as to evaluate the efficiency of therapeutic agents under testing and to thus accelerate the therapeutic discovery process. In this Special Issue, the current knowledge as well as future perspectives on the role of biomarkers in screening, diagnosis, treatment and follow-up of Alzheimer's disease will be discussed.

Dr. Chiara Villa
Guest Editor

mdpi.com/si/33684

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us